New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 12, 2014
07:12 EDTSGENSeattle Genetics 2014 Adcetris guidance good, says RBC Capital
RBC Capital noted that Seattle Genetics' guidance for 2014 Adcetris sales was in-line with RBC Capital's estimate but below the consensus outlook. RBC Capital thinks the consensus outlook was flawed as it failed to take into account the lack of major catalysts for the drug until possibly late 2014. RBC Capital keeps an Outperform rating on Seattle Genetics.
News For SGEN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 7, 2015
08:04 EDTSGENSeattle Genetics initiates Phase 1/2 trial of ADCETRIS
Seattle Genetics (SGEN) announced that it has initiated a phase 1/2 clinical trial of ADCETRIS in combination with Opdivo for patients with relapsed or refractory Hodgkin lymphoma, or HL, after failure of frontline treatment. The trial is being conducted under a previously announced clinical trial collaboration agreement with Bristol-Myers Squibb (BMY). ADCETRIS is an antibody-drug conjugate directed to CD30, a defining marker of classical HL, which combines the targeting ability of a monoclonal antibody with a highly potent cell-killing agent. Opdivo is a human antibody that targets and inhibits the programmed death receptor-1, resulting in T-cell activation. Opdivo is part of a new class of cancer immunotherapy treatments known as checkpoint inhibitors, which are designed to harness the body's own immune system in fighting cancer by targeting distinct regulatory components of the immune system. A second trial under the collaboration is planned to begin later in 2015 for relapsed or refractory B-cell and T-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use